查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1284229

甲狀腺疾病治療市場預測至 2028 年——按疾病類型、給藥途徑、藥物類別、藥物類型、分銷渠道和地區進行的全球分析

Thyroid Gland Disorders Treatment Market Forecasts to 2028 - Global Analysis By Type of Disorder, Route of Administration, Drug Class, Drug Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2022 年全球甲狀腺疾病治療市場規模將達到 272685 萬美元，預計到 2028 年將達到 382451 萬美元，預計複合年增長率為 5.8% .

甲狀腺是一種內分泌腺，可促進有助於控制身體新陳代謝的激素分泌。 當甲狀腺產生過多或過少的甲狀腺激素時，它會干擾身體的新陳代謝和功能。 甲狀腺疾病的主要原因之一是體內缺乏碘。 據信全世界有超過 20 億人面臨碘缺乏症的風險，其中一半被誤診。 此外，這些人中的大多數都沒有被確診，而且大多數都在欠發達國家。 功能或結構問題可導致甲狀腺疾病。 據說婦女和老年人更容易感染這種疾病。

根據美國衛生與公共服務部公佈的數據，美國每年約有 1.2% 的人患有甲狀腺功能減退症。 此外，據說女性患甲狀腺疾病的可能性是男性的 2 到 10 倍。

市場動態：

驅動程序

主持人：診斷和治療技術的進步

甲狀腺疾病治療市場見證了診斷和治療技術的多項進步，有助於改善患者的治療效果和生活質量。 就診斷技術而言，超聲是一種非侵入性成像技術，它使用聲波來創建甲狀腺圖像。 它通常用於檢測甲狀腺結節，並有助於確定結節是癌性還是良性。 細針穿刺活檢也是一種診斷程序，其中使用細針從甲狀腺中取出和分析細胞。 診斷和治療技術的進步將顯著改善甲狀腺疾病治療市場，從而改善患者的治療效果和生活質量，並在預測期內加速市場增長。

約束

副作用和並發症

如果不及時治療或治療不當，甲狀腺疾病會導致多種並發症。 甲狀腺疾病的治療取決於疾病的類型和嚴重程度，但所有治療都有副作用和並發症的風險。 甲狀腺疾病有有效的治療方法，但所有治療方法都有副作用和並發症的風險。 必須與醫療保健專業人員密切合作以管理治療並監測潛在的副作用和並發症，這預計會阻礙霧計算市場的增長。

機會

甲狀腺疾病患病率增加

甲狀腺疾病在世界範圍內變得越來越普遍，影響了數百萬人。 甲狀腺疾病的患病率正在上升，有幾個因素促成了這一趨勢。 年齡是一個重要因素，患甲狀腺疾病的風險會隨著年齡的增長而增加。 女性也比男性更容易患甲狀腺疾病。 輻射和接觸某些化學物質等環境因素會增加患甲狀腺疾病的風險。 此外，有甲狀腺疾病家族史會增加患甲狀腺疾病的風險。

威脅

嚴格的監管政策

甲狀腺疾病治療市場受到嚴格的監管政策的約束，以確保治療的安全性和有效性。 這些政策由美國的食品和藥物管理局 (FDA)、歐洲的歐洲藥品管理局 (EMA) 以及世界其他國家的監管機構等監管機構實施。 甲狀腺疾病治療的監管政策包括臨床前和臨床試驗的要求，以確定藥物、醫療器械和其他治療的安全性和有效性。 這些試驗必須遵守嚴格的研究設計、患者招募和倫理考慮指南。 嚴格的監管政策對甲狀腺治療市場的公司構成挑戰，但對於確保患者治療的安全性和有效性至關重要。

COVID-19 的影響：

在 COVID 期間，大多數行業都受到了不利影響。 這是由於世界各地的政府機構實施的各種預防性封鎖和其他限制措施已對其各自的生產和供應鏈運營造成巨大破壞。 全球治療甲狀腺疾病的藥物市場也是如此。 此外，隨著大多數人的總體經濟狀況受到此次疫情的嚴重影響，人們更願意削減預算中的非必要支出，消費者需求正在下降。

甲亢段預計在預測期內最大

甲狀腺功能亢進症是由甲狀腺分泌過多甲狀腺素引起的。 預計該領域在預測期內將有顯著發展，部分原因是全球甲狀腺癌和甲狀腺功能亢進症的患病率上升。 StatPearls 發表於 2022 年 7 月的一篇文章發現，亞臨床甲亢對 65 歲以上女性的影響多於男性，而明顯甲亢的發生率為每 1000 名女性 0.4 例，每 1000 名男性 0.1 例，並且隨年齡變化。 由於甲狀腺功能亢進症的高患病率，預計會出現針對這種疾病的尖端療法，這有望在預測期內推動市場擴張。

預計左旋甲狀腺素在預測期內的複合年增長率最高。

對於甲狀腺功能減退症的治療，預計左旋甲狀腺素在預測期內將保持最高的複合年增長率。 甲狀腺功能減退症和甲狀腺功能亢進症領域在用於治療甲狀腺問題的藥物市場中佔據主導地位。 左旋甲狀腺素和碘塞羅寧是用於治療甲狀腺功能減退症的藥物示例。 甲狀腺疾病治療市場的主要驅動因素是甲狀腺疾病的全球患病率不斷上升、新興國家和發達國家對含左旋甲狀腺素藥物的需求不斷增加，以及領先的甲狀腺藥物製造商創造了尖端療法。我們正在以由於我們持續致力於

市場份額最高的地區：

北美在預期期間的收入份額最大。 該地區的高收入份額部分歸因於高效醫療設施的存在、人們知識水平高以及可用治療範圍廣泛。 該地區正在見證製藥公司和政府機構之間的戰略合作夥伴關係，特別是在仿製藥的生產和提高醫療保健專業人員的意識方面。 正因如此，北美市場的利潤頗豐。 例如，Genzyme 計劃與 Veracyte 合作，為管理甲狀腺問題提供個性化治療。

複合年增長率最高的地區：

預計亞太地區在預測期內的增長率最快。 由於該地區甲狀腺疾病的高患病率和不斷增加的醫療支出，該地區的製造商正專注於開發成本更低、效率更高的產品。 受原材料和勞動力成本低廉的吸引，全球企業也在該地區投資當地公司。 此外，世界各地還舉辦了甲狀腺宣傳月，以提高人們對甲狀腺相關疾病和甲狀腺癌的認識。 這些努力有望促進早期發現和早期治療，推動預測期內的市場增長。

主要發展：

2022 年 11 月：美國子公司 Zydus Lifesciences 獲得美國聯邦藥物管理局 (USFDA) 的左旋甲狀腺素鈉注射液上市許可，用於治療甲狀腺激素缺乏症。

2022 年 5 月，美國食品和藥物管理局 (FDA) 批准了禮來公司新的每週一次的 GIP（葡萄糖依賴性促胰島素多□）和 GLP-1（胰高血糖素樣□-1））批准的替西□注射液，一種受體激動劑，可作為飲食和運動的輔助手段，以改善成人 2 型糖尿病患者的血糖控制。

2021 年 9 月，Exelixis Inc. 宣布 CABOMETYX（卡博替尼）用於在先前針對血管內皮生長因子受體 (VEGFR) 的治療後出現進展的局部晚期或轉移性分化型甲狀腺癌 (DTC)。獲得 USFDA 批准用於治療放射性碘-難治性或不合格的成人和兒童患者。

本報告內容

  • 區域和國家級細分市場的市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場趨勢（驅動因素、制約因素、機會、威脅、挑戰、投資機會、建議）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射關鍵共同趨勢。
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制優惠：

購買此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶的要求對主要國家/地區的市場估計/預測/複合年增長率（注意：基於可行性檢查）。
  • 競爭基準
    • 根據產品組合、區域影響力和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二級研究來源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球甲狀腺疾病治療市場：按疾病類型分類

  • 甲減
  • 甲亢
  • 其他

第 6 章全球甲狀腺疾病治療市場：按給藥途徑

  • 口語
  • 腸外
  • 靜脈注射
  • 其他

第7章 全球甲狀腺疾病治療市場：按藥物分類

  • 硫代□胺
  • 離子抑製劑
  • 激素釋放抑製劑
  • 其他

第 8 章全球甲狀腺疾病治療市場：按藥物類型分類

  • 左旋甲狀腺素
  • 碘塞羅寧
  • 丙基硫氧嘧啶
  • 咪唑化合物
  • 其他

第 9 章。全球甲狀腺疾病治療市場：按分銷渠道

  • 批發分銷
  • 零售店
  • 在線藥店
  • 郵購藥房
  • 其他分銷渠道

第 10 章全球甲狀腺疾病治療市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第11章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第十二章公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • ALLERGAN
  • Alvogen ehf
  • Amgen Inc.
  • Aspen
  • Elexis Inc.
  • GlaxoSmithKline Plc
  • GSK Plc
  • IBSA Pharma（IBSA Group）
  • Lannett Co. Inc.
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • RLC Labs Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: SMRC23061

According to Stratistics MRC, the Global Thyroid Gland Disorders Treatment Market is accounted for $2726.85 million in 2022 and is expected to reach $3824.51 million by 2028 growing at a CAGR of 5.8% during the forecast period. A thyroid gland is an endocrine gland that promotes hormones that assist in controlling the body's metabolism. The body's metabolism and functionality are hampered when the thyroid gland produces too many or insufficient thyroid hormones. One of the main causes of thyroid diseases is a shortage of iodine in the body. More than 2 billion people are thought to be at risk of iodine deficiency globally, and half of those individuals are misdiagnosed. The majority of these individuals are undiagnosed, with the majority being in underdeveloped nations. Functional or structural problems can cause thyroid diseases. Women and the elderly are more likely to have this illness.

According to numbers published by the U.S. Department of Health and Human Services, around 1.2% people in the U.S. suffer from hypothyroidism each year. Moreover, women 2-10 times more susceptible than men to develop thyroid conditions.

Market Dynamics:

Driver:

Advancements in diagnostic and treatment technologies

There have been several advancements in diagnostic and treatment technologies in the Thyroid Gland Disorders Treatment Market, leading to improved patient outcomes and quality of life. In terms of diagnostic technologies, ultrasound is a non-invasive imaging technique that uses sound waves to create images of the thyroid gland. It is often used to detect thyroid nodules and can help determine whether a nodule is cancerous or benign. Fine-needle aspiration biopsy is another diagnostic technique that involves using a thin needle to extract cells from the thyroid gland for analysis. Advancements in diagnostic and treatment technologies have significantly improved the Thyroid Gland Disorders Treatment Market, leading to better patient outcomes and quality of life, which will accelerate market growth over the course of the forecast period.

Restraint:

Side effects and complications

Thyroid gland disorders can lead to several complications if left untreated or if treatment is not managed correctly. Treatment options for thyroid gland disorders vary depending on the specific type and severity of the disorder, but all treatments carry the risk of side effects and complications. While there are effective treatments available for thyroid gland disorders, all treatments carry the risk of side effects and complications. It is essential to work closely with a healthcare provider to manage treatment and monitor for any potential side effects or complications, which are projected to impede the fog computing market's growth.

Opportunity:

Growing prevalence of thyroid gland disorders

Thyroid gland disorders are increasingly prevalent worldwide, affecting millions of people. The prevalence of thyroid gland disorders is on the rise, and several factors contribute to this trend. Age is a significant factor, with the risk of developing a thyroid disorder increasing as one grows older. Women are also more likely to develop thyroid gland disorders than men. Environmental factors, such as exposure to radiation or certain chemicals, can increase the risk of developing a thyroid disorder. A family history of thyroid gland disorders also increases the risk of developing the condition.

Threat:

Stringent regulatory policies

The Thyroid Gland Disorders Treatment Market is subject to stringent regulatory policies to ensure the safety and efficacy of treatments. These policies are put in place by regulatory bodies such as the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in Europe, and other national regulatory agencies worldwide. Regulatory policies for thyroid gland disorders treatments include requirements for preclinical and clinical trials to establish the safety and efficacy of drugs, medical devices, and other treatments. These trials must adhere to strict guidelines for study design, patient recruitment, and ethical considerations. While stringent regulatory policies can create challenges for companies in the Thyroid Gland Disorders Treatment Market, they are essential to ensure the safety and efficacy of treatments for patients.

COVID-19 Impact:

Over the time frame of COVID, the majority of industries saw adverse effects. This can be attributed to the enormous disruptions that various precautionary lockdowns and other limitations that were imposed by governing agencies around the world caused in their respective production and supply-chain operations. The same is true for the global market for treatments for thyroid gland disorders. Additionally, consumer demand has now decreased as people have become more motivated to cut non-essential spending from their own budgets, as the general economic situation of the majority of people has been badly impacted by this outbreak.

The Hyperthyroidism segment is expected to be the largest during the forecast period

The overproduction of thyroxin by the thyroid gland results in hyperthyroidism. The category is anticipated to develop significantly over the projected period due to factors like the rising prevalence of thyroid cancer and hyperthyroidism around the world. Subclinical hyperthyroidism affects more women over 65 than males, according to a StatPearls article published in July 2022, whereas rates of overt hyperthyroidism are 0.4 per 1000 women and 0.1 per 1000 men and vary with age. The high prevalence of hyperthyroidism is anticipated to open up prospects for the creation of cutting-edge therapies for the condition, which is anticipated to fuel market expansion over the course of the projected period.

The levothyroxine segment is expected to have the highest CAGR during the forecast period

Throughout the projected period, levothyroxine will continue to see the highest CAGR for the treatment of hypothyroidism. The hypothyroidism and hyperthyroidism segments make up the majority of the market for drugs used to treat thyroid gland problems. Levothyroxine and liothyronine are examples of medications used to treat hypothyroidism. The market for the treatment of thyroid disorders is growing at a moderate rate, primarily as a result of the increased global prevalence of thyroid disorders, rising demand for levothyroxine-containing medications in both developing and developed regions, and ongoing efforts by top thyroid drug producers to create cutting-edge therapeutics.

Region with largest share:

Over the course of the anticipated period, North America accounted for the biggest revenue share. One reason for its high revenue share is the existence of efficient healthcare facilities, higher knowledge levels among people, and a wide range of available treatment alternatives. In the region, strategic alliances between pharmaceutical firms and governmental bodies are growing, especially to create generic medications and raise awareness among healthcare professionals. Because of this, the market in North America is quite profitable. For instance, Genzyme will offer tailored treatments for the management of thyroid gland problems in collaboration with Veracyte Inc.

Region with highest CAGR:

During the forecast period, Asia-Pacific is anticipated to have the fastest growth rate. Due to the increasing prevalence of thyroid disorders in the region and rising healthcare expenditure, as manufacturers in this region are focusing on the development of low-cost products with higher efficiency. In addition, global players are investing in local companies in the region, attracted by the lower cost of raw material and labor. Additionally, Thyroid Awareness Month was celebrated worldwide to raise awareness regarding thyroid-related diseases and thyroid cancer. Such initiatives are expected to boost early detection and treatment, which is expected to propel the market growth during the forecast period.

Key players in the market:

Some of the key players in Thyroid Gland Disorders Treatment Market include Abbott Laboratories, AbbVie Inc., ALLERGAN, Alvogen ehf, Amgen Inc., Aspen, Elexis Inc., GlaxoSmithKline Plc, GSK Plc, IBSA Pharma (IBSA Group), Lannett Co. Inc., Merck KGaA, Mylan N.V., Novartis AG, Pfizer Inc., RLC Labs Inc., Sanofi, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd. and Viatris Inc.

Key Developments:

In Nov 2022: Zydus Lifesciences, a US-based subsidiary, received approval from the USFDA to market Levothyroxine Sodium injection, used to treat thyroid hormone deficiency.

In May 2022: The United States Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection, Eli Lilly and Company's new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

In September 2021, Exelixis Inc. received USFDA approval for CABOMETYX (cabozantinib) for the treatment of adult and pediatric patients with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible.

Type of Disorders Covered:

  • Hypothyroidism
  • Hyperthyroidism
  • Other Types of Disorders

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Intravenous Route
  • Other Routes of Administrations

Drug Classes Covered:

  • Thioamides
  • Ionic Inhibitors
  • Hormone-release Inhibitors
  • Other Drug Classes

Drug Types Covered:

  • Levothyroxine
  • Liothyronine
  • Propylthiouracil
  • Imidazole-Based Compounds
  • Other Drug Types

Distribution Channels Covered:

  • Wholesale Distribution
  • Retail Stores
  • Online Pharmacy
  • Mail-Order Pharmacy
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Thyroid Gland Disorders Treatment Market, By Type of Disorder

  • 5.1 Introduction
  • 5.2 Hypothyroidism
  • 5.3 Hyperthyroidism
  • 5.4 Other Types of Disorders

6 Global Thyroid Gland Disorders Treatment Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Parenteral
  • 6.4 Intravenous Route
  • 6.5 Other Routes of Administrations

7 Global Thyroid Gland Disorders Treatment Market, By Drug Class

  • 7.1 Introduction
  • 7.2 Thioamides
  • 7.3 Ionic Inhibitors
  • 7.4 Hormone-release Inhibitors
  • 7.5 Other Drug Classes

8 Global Thyroid Gland Disorders Treatment Market, By Drug Type

  • 8.1 Introduction
  • 8.2 Levothyroxine
  • 8.3 Liothyronine
  • 8.4 Propylthiouracil
  • 8.5 Imidazole-Based Compounds
  • 8.6 Other Drug Types

9 Global Thyroid Gland Disorders Treatment Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Wholesale Distribution
  • 9.3 Retail Stores
  • 9.4 Online Pharmacy
  • 9.5 Mail-Order Pharmacy
  • 9.6 Other Distribution Channels

10 Global Thyroid Gland Disorders Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 AbbVie Inc.
  • 12.3 ALLERGAN
  • 12.4 Alvogen ehf
  • 12.5 Amgen Inc.
  • 12.6 Aspen
  • 12.7 Elexis Inc.
  • 12.8 GlaxoSmithKline Plc
  • 12.9 GSK Plc
  • 12.10 IBSA Pharma (IBSA Group)
  • 12.11 Lannett Co. Inc.
  • 12.12 Merck KGaA
  • 12.13 Mylan N.V.
  • 12.14 Novartis AG
  • 12.15 Pfizer Inc.
  • 12.16 RLC Labs Inc.
  • 12.17 Sanofi
  • 12.18 Takeda Pharmaceutical Company Limited
  • 12.19 Teva Pharmaceutical Industries Ltd.
  • 12.20 Viatris Inc.

List of Tables

  • Table 1 Global Thyroid Gland Disorders Treatment Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
  • Table 3 Global Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
  • Table 4 Global Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
  • Table 5 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
  • Table 6 Global Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 7 Global Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
  • Table 8 Global Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 9 Global Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
  • Table 10 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
  • Table 11 Global Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 12 Global Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
  • Table 13 Global Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
  • Table 14 Global Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
  • Table 15 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
  • Table 16 Global Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
  • Table 17 Global Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
  • Table 18 Global Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
  • Table 19 Global Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
  • Table 20 Global Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
  • Table 21 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
  • Table 22 Global Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 23 Global Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
  • Table 24 Global Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
  • Table 25 Global Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
  • Table 26 Global Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
  • Table 27 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 28 North America Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 29 North America Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
  • Table 30 North America Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
  • Table 31 North America Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
  • Table 32 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
  • Table 33 North America Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 34 North America Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
  • Table 35 North America Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 36 North America Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
  • Table 37 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
  • Table 38 North America Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 39 North America Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
  • Table 40 North America Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
  • Table 41 North America Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
  • Table 42 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
  • Table 43 North America Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
  • Table 44 North America Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
  • Table 45 North America Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
  • Table 46 North America Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
  • Table 47 North America Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
  • Table 48 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
  • Table 49 North America Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 50 North America Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
  • Table 51 North America Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
  • Table 52 North America Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
  • Table 53 North America Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
  • Table 54 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 55 Europe Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 56 Europe Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
  • Table 57 Europe Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
  • Table 58 Europe Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
  • Table 59 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
  • Table 60 Europe Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 61 Europe Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
  • Table 62 Europe Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 63 Europe Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
  • Table 64 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
  • Table 65 Europe Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 66 Europe Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
  • Table 67 Europe Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
  • Table 68 Europe Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
  • Table 69 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
  • Table 70 Europe Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
  • Table 71 Europe Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
  • Table 72 Europe Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
  • Table 73 Europe Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
  • Table 74 Europe Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
  • Table 75 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
  • Table 76 Europe Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 77 Europe Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
  • Table 78 Europe Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
  • Table 79 Europe Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
  • Table 80 Europe Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
  • Table 81 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 82 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 83 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
  • Table 84 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
  • Table 85 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
  • Table 86 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
  • Table 87 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 88 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
  • Table 89 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 90 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
  • Table 91 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
  • Table 92 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 93 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
  • Table 94 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
  • Table 95 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
  • Table 96 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
  • Table 97 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
  • Table 98 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
  • Table 99 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
  • Table 100 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
  • Table 101 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
  • Table 102 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
  • Table 103 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 104 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
  • Table 105 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
  • Table 106 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
  • Table 107 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
  • Table 108 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 109 South America Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 110 South America Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
  • Table 111 South America Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
  • Table 112 South America Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
  • Table 113 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
  • Table 114 South America Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 115 South America Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
  • Table 116 South America Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 117 South America Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
  • Table 118 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
  • Table 119 South America Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 120 South America Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
  • Table 121 South America Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
  • Table 122 South America Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
  • Table 123 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
  • Table 124 South America Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
  • Table 125 South America Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
  • Table 126 South America Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
  • Table 127 South America Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
  • Table 128 South America Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
  • Table 129 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
  • Table 130 South America Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 131 South America Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
  • Table 132 South America Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
  • Table 133 South America Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
  • Table 134 South America Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
  • Table 135 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 136 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 137 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
  • Table 138 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
  • Table 139 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
  • Table 140 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
  • Table 141 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 142 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
  • Table 143 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 144 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
  • Table 145 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
  • Table 146 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 147 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
  • Table 148 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
  • Table 149 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
  • Table 150 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
  • Table 151 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
  • Table 152 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
  • Table 153 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
  • Table 154 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
  • Table 155 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
  • Table 156 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
  • Table 157 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 158 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
  • Table 159 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
  • Table 160 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
  • Table 161 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
  • Table 162 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)